HeartBeam Partners With HeartNexus to Expand Remote Cardiac Monitoring Services
HeartBeam's partnership with HeartNexus enables 24/7 remote cardiology services and real-time ECG interpretation, expanding access to medical-grade cardiac care outside traditional healthcare facilities.
HeartBeam has announced a strategic partnership with HeartNexus Inc. to deliver comprehensive 24/7 remote cardiology services and real-time ECG interpretation. The collaboration represents a significant advancement in making medical-grade cardiac monitoring accessible beyond traditional healthcare settings, addressing critical gaps in cardiac care availability.
The partnership enables HeartBeam to offer continuous cardiology reader services for patients experiencing cardiac symptoms outside conventional care environments. Using HeartBeam's patented 3D technology, patients can capture 30-second, cable-free ECG recordings whenever symptoms occur and transmit the data directly to HeartNexus cardiologists for immediate interpretation. This capability is particularly important for patients who experience cardiac symptoms at unpredictable times or outside regular medical facility hours.
Robert Eno, CEO of HeartBeam, emphasized the strategic importance of the collaboration, stating that working with HeartNexus accelerates the company's mission to make medical-grade cardiac monitoring accessible beyond the walls of a medical facility. The partnership expands HeartBeam's ecosystem with real-time cardiology feedback and lays the foundation for future integration of AI wellness and wearable features, positioning the company at the forefront of remote cardiac care innovation.
HeartBeam's technology platform represents a significant advancement in cardiac monitoring. The company is creating the first-ever cable-free device capable of collecting ECG signals in 3D from three non-coplanar directions and synthesizing the signals into a 12-lead ECG. This platform technology is designed for portable devices that can be used wherever the patient is located, delivering actionable heart intelligence to physicians who can then identify cardiac health trends and acute conditions while directing patients to appropriate care outside medical facilities.
The regulatory landscape for HeartBeam's technology continues to evolve. The company's 3D ECG technology received FDA clearance for arrhythmia assessment in December 2024, while the 12-Lead ECG synthesis software remains under FDA review. HeartBeam maintains a strong intellectual property position with over 20 issued patents related to technology enablement, providing competitive protection for its innovative approach to cardiac monitoring.
For additional information about HeartBeam's developments, readers can access the company's newsroom at https://ibn.fm/BEAT. The full press release detailing the partnership is available at https://ibn.fm/HqwuQ. Legal disclaimers and terms of use applicable to all content are provided at http://IBN.fm/Disclaimer.